What one share of Cognition Therapeutics holds
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina.
Cognition Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.19 |
|---|---|
| Cash and investments | $0.36 |
| Book value | $0.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$23.76 | $0.02 | −$6.78 | — | −$126.55 |
| 2021 | — | −$3.13 | $0.01 | −$0.70 | — | — |
| 2022 | — | −$0.91 | $0.01 | −$0.79 | — | $1.39 |
| 2023 | — | −$0.86 | $0.00 | −$0.54 | — | $0.76 |
| 2024 | — | −$0.85 | $0.00 | −$0.72 | — | $0.31 |
| 2025 | — | −$0.32 | — | — | — | $0.39 |
Common questions about Cognition Therapeutics
How much does one share of Cognition Therapeutics earn?
Over the last 12 months, Cognition Therapeutics lost $0.19 for each share.
Does Cognition Therapeutics pay a dividend?
Cognition Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cognition Therapeutics’s book value per share?
Cognition Therapeutics’s book value is $0.35 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cognition Therapeutics have?
Each share of Cognition Therapeutics has $0.36 of cash and investments, as of June 30, 2026.
Has Cognition Therapeutics bought back shares?
Cognition Therapeutics’s share count rose about 14221% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.